•The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for MYQORZO in the UK for obstructive hypertrophic cardiomyopathy.
•The drug received positive guidance from the National Institute for Health and Care Excellence (NICE) for use in England and Wales.